Pfizer 3Q profit falls 14 pct on generic Lipitor (Update)

by Linda A. Johnson

(AP)—Drug giant Pfizer Inc. said Thursday that its third-quarter profit fell 14 percent as sales plunged, mainly due to U.S. generic competition to cholesterol fighter Lipitor, long the world's top-selling drug.

Sales of Lipitor, which is still under patent in some other countries, dropped 71 percent worldwide to $749 million and nosedived 87 percent in the U.S.

It had plenty of company: Sales for more than two-thirds of Pfizer's medicines declined, most by 10 percent or more and mainly because of generic competition. That cut prescription drug revenue by about $2 billion.

But even Prevnar 13, a shot against ear infections, deadly meningitis and other bacterial diseases that is the top-selling vaccine in history, saw sales fall by 12 percent, to $868 million. It's still protected by patents, so the drop could indicate that sales have hit a wall as most children in developing countries have already been vaccinated.

The New York-based maker of pain reliever Lyrica said net income was $3.21 billion, or 43 cents per share. That was down from $3.74 billion, or 48 cents per share, a year earlier.

Excluding one-time items, earnings were 53 cents per share. Analysts expected 52 cents. The items included a $1.1 billion gain from a tax settlement, a $491 million charge related to an agreement with the U.S. Justice Department to end an investigation into past promotion of the immunosuppressant drug Rapamune for unapproved uses, and other charges for restructuring, productivity initiatives and the gradual writedown in the value of some assets.

Revenue fell 16 percent to $13.98 billion, well below expectations for $14.66 billion. Unfavorable exchange rates cut worldwide revenue by 4 percent. Excluding the currency impact, total international sales fell 7 percent, to $8.35 billion. U.S. sales dropped 18 percent, to $5.63 billion.

Revenue from prescription drugs dropped 18 percent, to $12.12 billion, as four of its five segments fared poorly. Sales were down sharply for primary care and specialty care medicines and down by a percent or two for cancer drugs and drugs sold in emerging markets such as China and India. Only the established products business, which sells popular but off-patent medicines, saw sales rise, by 7 percent to $2.4 billion—and that was because sales of Lipitor in the U.S. and Japan were shifted to that category from primary care sales.

Lipitor, which once brought in as much as $13 billion a year, got generic competition on Nov. 30, 2011. Pfizer slowed defections while it had limited, slightly cheaper generic competition through May, with big rebates to insurers and $4 copayment offers for most patients staying on Lipitor. But prices plunged when multiple generics hit the market at the end of May. Pfizer then ended the insurer rebates and most patients switched to generics.

The bright spots were increases of 14 percent to $1.04 billion for what's now Pfizer's top seller, Lyrica for fibromyalgia and other pain; 5 percent for painkiller Celebrex, to $676 million, and 5 percent for erectile dysfunction drug Viagra, to $517 million.

Sales of consumer health products such as pain relievers Advil and Anbesol increased 2 percent to $780 million, helped by two small acquisitions. Veterinary medicine sales, including the Convenia antibiotic for dogs and cats, fell by 2 percent to $1.02 billion.

Despite the lower sales, Pfizer raised its 2012 profit forecast, to $1.30 to $1.38 per share, from $1.21 to $1.36 per share. But the company reduced the top end of its revenue forecast by $1 billion. The new forecast is for $58 billion to $59 billion.

CEO Ian Read noted three new drugs have recently been approved in the U.S. or Europe, and two others that could be big sellers could get approved soon.

"Given our demonstrated ability to advance our strategic initiatives, I believe we are well-positioned to deliver attractive returns for our shareholders over time," Read said in a statement.

The company noted its board of directors has authorized a new $10 billion share repurchase program that's to start when Pfizer completes the pending sale of its nutrition business for $11.85 billion to Swiss food and drink giant Nestle SA. That's expected to happen in the next few months.

The company has bought back about 302 million shares in the past 12 months, reducing the total outstanding to 7.5 billion, and has another $4.1 billion remaining under its current buyback program.

Pfizer's stock fell 28 cents, or 1.1 percent, at $24.56 in premarket trading.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer 2Q net income rises 25 pct on lower costs

Jul 31, 2012

Drugmaker Pfizer Inc.'s second-quarter net income jumped 25 percent as sharply lower costs for production, marketing and restructuring more than offset a plunge in revenue from cholesterol fighter Lipitor ...

Retailers sue Pfizer, charge generic Lipitor delay

Jul 07, 2012

(AP) — Five large U.S. drug and grocery chains are suing Pfizer Inc. and a second drugmaker, alleging they conspired to delay sales of cheap generic versions of the blockbuster cholesterol drug Lipitor.

Merck's 2Q net falls on charges, but sales rise

Jul 27, 2012

Merck & Co.'s second-quarter net income fell 11.4 percent as slightly higher sales were offset by acquisition and restructuring costs. However, the drugmaker beat Wall Street expectations, and Merck shares ...

J&J Q3 net income drops 7 percent on higher costs

Oct 16, 2012

Johnson & Johnson's third-quarter profit fell 7 percent as increased research and production costs offset higher sales for its medicines and medical devices and new revenue from its biggest acquisition ever.

Oracle's profit tops Street, but worries surface

Jun 23, 2011

(AP) -- Oracle Corp.'s latest quarterly results Thursday underscore the critical role its software business plays despite its push to become a more well-rounded technology vendor by selling computer servers.

Recommended for you

Exploring 3-D printing to make organs for transplants

Jul 30, 2014

Printing whole new organs for transplants sounds like something out of a sci-fi movie, but the real-life budding technology could one day make actual kidneys, livers, hearts and other organs for patients ...

High frequency of potential entrapment gaps in hospital beds

Jul 30, 2014

A survey of beds within a large teaching hospital in Ireland has shown than many of them did not comply with dimensional standards put in place to minimise the risk of entrapment. The report, published online in the journal ...

Key element of CPR missing from guidelines

Jul 29, 2014

Removing the head tilt/chin lift component of rescue breaths from the latest cardiopulmonary resuscitation (CPR) guidelines could be a mistake, according to Queen's University professor Anthony Ho.

Burnout impacts transplant surgeons (w/ Video)

Jul 28, 2014

Despite saving thousands of lives yearly, nearly half of organ transplant surgeons report a low sense of personal accomplishment and 40% feel emotionally exhausted, according to a new national study on transplant surgeon ...

User comments